Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
IMVT
vs
S&P 500
IMVT
S&P 500
Over the past 12 months, IMVT has significantly outperformed S&P 500, delivering a return of +103% compared to S&P 500's +15% growth.
Stocks Performance
IMVT vs S&P 500
Performance Gap
IMVT vs S&P 500
Performance By Year
IMVT vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Immunovant Inc
Glance View
Immunovant is a biotechnology company that develops medicines for autoimmune diseases, which are conditions where the immune system attacks the body’s own tissues. Its main work is on antibody drugs that block the FcRn pathway, a mechanism that helps certain harmful antibodies stay in the bloodstream. By lowering those antibodies, the company aims to treat diseases such as myasthenia gravis, thyroid eye disease, and other immune-driven disorders. The company does not sell a broad portfolio of commercial drugs. Instead, it earns money mainly by funding and advancing its drug candidates through research, clinical trials, and regulatory work, often with support from partners and investors rather than product sales. If its programs succeed, it would likely make money later by licensing the drugs, partnering with larger drugmakers, or eventually selling approved treatments into specialty physician markets. Immunovant’s business is different from a traditional drug company because it is focused on a small number of highly targeted therapies rather than many products. That makes the company’s value tied closely to whether its lead programs work in clinical testing and whether doctors and regulators see enough benefit for patients with serious autoimmune disease.
